Bacteremic pneumonia caused by Enterococcus hirae in a subject receiving regorafenib / Neumonía bacteriémica causada por Enterococcus hirae en un paciente tratado con regorafenib

INTRODUCTION: Infections due to Enterococcus hirae have rarely been reported in humans but are not uncommon in mammals and birds. We describe a case of E. hirae bacteremia and pneumonia in a bird breeder and its potential relationship with regorafenib, a tirosin kinase inhibitor (TKI). METHODS: Descriptive study and review of the literature through a PubMed search of the cases described previously to date. RESULTS: Only seventeen cases have been described, mainly endocarditis, pyelonephritis, and intraabdominal infections. No cases of pneumonia have been reported so far. The recent increase in TKI use opens a new field to explore in infectious diseases due to both the exposure to these immunosuppressive drugs and the increased survival of subjects with severe underlying comorbidities. CONCLUSIÓN: In patients in contact with birds, immunosuppressed by their underlying morbidities and treated with regorafenib, clinicians should be aware of an increased risk of unusual potentially severe infections

INTRODUCCIÓN: La infección por Enterococcus hirae se ha reportado raramente en humanos, pero no es infrecuente en mamíferos y aves. Describimos un caso de neumonía bacteriémica por Enterococcus hirae, y su posible relación con regorafenib, un inhibidor de la tirosina quinasa (TKI, por sus siglas en inglés). MÉTODOS: Estudio descriptivo y revisión de la literatura mediante una búsqueda en PubMed de los casos descritos anteriormente hasta la fecha. RESULTADOS: Solo se han publicado 17 casos, principalmente endocarditis, pielonefritis e infecciones intraabdominales, sin ningún caso de neumonía. El reciente incremento en el uso de la TKI abre la puerta a un nuevo campo a explorar en enfermedades infecciosas debido tanto a la exposición a estos fármacos como al incremento en la supervivencia de individuos con importantes comorbilidades subyacentes. CONCLUSIÓN: En pacientes en contacto cercano con aves, inmunodeprimidos por sus comorbilidades y en tratamiento con regorafenib, podría existir un mayor riesgo de infecciones inusuales potencialmente graves

Bacteremic pneumonia caused by Enterococcus hirae in a subject receiving regorafenib.

INTRODUCTION: Infections due to Enterococcus hirae have rarely been reported in humans but are not uncommon in mammals and birds. We describe a case of E. hirae bacteremia and pneumonia in a bird breeder and its potential relationship with regorafenib, a tirosin kinase inhibitor (TKI). METHODS: Descriptive study and review of the literature through a PubMed search of the cases described previously to date. RESULTS: Only seventeen cases have been described, mainly endocarditis, pyelonephritis, and intraabdominal infections. No cases of pneumonia have been reported so far. The recent increase in TKI use opens a new field to explore in infectious diseases due to both the exposure to these immunosuppressive drugs and the increased survival of subjects with severe underlying comorbidities. CONCLUSION: In patients in contact with birds, immunosuppressed by their underlying morbidities and treated with regorafenib, clinicians should be aware of an increased risk of unusual potentially severe infections.